anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The differences in outcomes after aneurysmal subarachnoid hemorrhage (aSAH) between the sexes have not been concretely determined. This study aimed to evaluate the differences in epidemiology, outcomes, and risk factors between male and female patients with aSAH.
METHODS: We performed a multicenter, retrospective study of patients with aSAH from 2017 to 2020. We investigated the epidemiological differences between the two sexes. Propensity score matching (PSM) was used to compare short-term outcomes between the sexes. Binary logarithmic regression was performed to investigate the odds ratio (OR) for dependent survival in patients of different sexes.
RESULTS: A total of 5,407 consecutive patients with aSAH were included in this study, and the female-to-male ratio was 1.8:1. The peak incidence of aSAH occurred in the 6th and 7th decades in males and females, respectively. There were more female patients with internal carotid artery or posterior communicating artery aneurysms (53.2%), and there were more male patients with anterior cerebral artery or anterior communicating artery aneurysms (43.2%). The incidence of multiple aneurysms was greater in female patients (21.5% vs. 14.2%, P < 0.001). There was no significant difference in outcomes before and after PSM at discharge. The dependent survival risk was related only to the clinical condition on admission in women. In addition, age > 50 years (OR 1.88, 95% confidence interval 1.17-3.02; P = 0.01) and hypertension (OR 1.81, 95% confidence interval 1.25-2.61; P = 0.002) were also risk factors for male patients.
CONCLUSIONS: There were more female patients with aneurysms than male patients in this study. Most aneurysm locations were different between the two groups. There was no significant difference in discharge outcomes before and after PSM. The risk factors for dependent survival were different between female and male patients.
The recommended adult (70 kg) dose of indium In 111 oxyquinoline labeled autologous leukocytes is 7.4 to 18.5 MBq, 200-500 µCi. Indium In 111 oxyquinoline solution is intended for the radiolabeling of autologous leukocytes. The indium In 111 oxyquinoline labeled autologous leukocytes are administered intravenously.

Imaging is recommended at approximately 24 hours post injection. Typically, anterior and posterior views of the chest, abdomen and pelvis should be obtained with other views as required.

Aseptic procedures and a shielded syringe should be employed in the withdrawal of indium In 111 oxyquinoline from the vial. Similar procedures should be employed during the labeling procedure and the administration of the labeled leukocytes to the patient. The user should wear waterproof gloves during the entire procedure. The patient's dose should be measured by a suitable radioactivity calibration system immediately before administration. At this time, the leukocyte preparation should be checked for gross clumping and red blood cell contamination.
BACKGROUND: Muscle mass is important for metastatic prostate cancer survival and quality of life (QoL). The backbone of treatment for men with metastatic castration sensitive prostate cancer (mCSPC) is androgen deprivation therapy (ADT) with an androgen signaling inhibitor. ADT is an effective cancer treatment, but it facilitates significant declines in muscle mass and adverse health outcomes important to mCSPC survivors, such as fatigue, and reductions in physical function, independence, insulin sensitivity, and QoL. In non-metastatic CSPC survivors, resistance training (RT) preserves muscle mass and improves these related health outcomes, but the biggest barrier to RT in CSPC survivors of all stages is fatigue. Creatine monohydrate supplementation coupled with RT (Cr + RT) may address this barrier since creatine plays a critical role in energy metabolism. Cr + RT in cancer-free older adults and other clinical populations improves muscle mass and related health outcomes. Evidence also suggests that creatine supplementation can complement cancer treatment. Thus, Cr + RT is a strategy that addresses gaps in survivorship needs of people with mCSPC. The purpose of this parallel, double-blind randomized controlled trial is to test the effects of 52-weeks of Cr + RT compared with placebo (PLA) and RT (PLA + RT) on muscle mass, other related health outcomes, and markers of cancer progression.
METHODS: We will carry out this trial with our team's established, effective, home-based, telehealth RT program in 200 mCSPC survivors receiving ADT, and evaluate outcomes at baseline, 24-, and 52-weeks. RT will occur twice weekly with elastic resistance bands, and an established creatine supplementation protocol will be used for supplementation delivery. Our approach addresses a major facilitator to RT in mCSPC survivors, a home-based RT program, while utilizing a supervised model for safety.
DISCUSSION: Findings will improve delivery of comprehensive survivorship care by providing a multicomponent, patient-centered lifestyle strategy to preserve muscle mass, improve health outcomes, and complement cancer treatment (NCT06112990).
<P>PROBLEM TO BE SOLVED: To provide a method for treating a mammal with immunological disorders, particularly autoimmune disease, and most preferably systemic lupus erythematosus (SLF).  <P>SOLUTION: The method includes oral administration of germination activated Ganoderma Lucidum spores (GLSs) to the mammal. The preferable daily dose of the GLSs is 1-20 g/person, most preferably 3-12 g/person. Additionally, a corticosteroid, such as prednisolone, can be co-administered with the GLSs to the mammal to achieve synergistic affect of treatment. The corticosteroid hormone is administered by oral, topical (solution, cream, lotion, ointment or the like) administration or injection. The preferable corticosteroid is Prednisolone, and oral administration is preferably carried out to a patient.  <P>COPYRIGHT: (C)2004,JPO
Cefepime for Injection USP and Dextrose Injection USP in the DUPLEX® Container is a flexible dual chamber container supplied in two strengths, 1 and 2 g cefepime. The diluent chamber contains approximately 50 mL of 5% Dextrose Injection.

Cefepime for Injection USP and Dextrose Injection USP is supplied sterile and nonpyrogenic in the DUPLEX Container packaged 24 single-dose units per case.

Store the unactivated unit at 20–25°C (68–77°F). Excursions permitted to 15–30°C (59–86°F). [See USP Controlled Room Temperature.] Do not freeze.

Not made with natural rubber latex, PVC or Di(2-ethylhexyl)phthalate (DEHP).

As with other cephalosporins, reconstituted Cefepime for Injection USP and Dextrose Injection USP tends to darken depending on storage conditions, within the stated recommendations. However, product potency is not adversely affected.

Use only if prepared solution is clear and free from particulate matter.
The Reach Out, Stay Strong, Essentials for New Mothers Program (ROSE), is an established Interpersonal Therapy (IPT)-oriented group intervention for postpartum depression. ROSE is a brief (5-session) program and its content addresses social support, role transition to motherhood, communication skills, and psychoeducation on PPD. ROSE consists of four 90-minute, weekly in person group sessions and one individual booster session. The first four sessions of ROSE will be delivered in groups of 6 to 20, and conducted in both English and Spanish. For the in-person groups, transportation via Uber will be provided to Denver Health Medical Center to reduce barriers to attendance.
Disclosed is a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more taxane derivatives, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or its salts. Examples of a taxane derivative are paclitaxel and docetaxel. Examples of solvents are alcohols, glycols, polyalkylene glycols, glycerol and glycofurol. Examples of polymers are polyvinylpyrrolidone and polyethylene glycol. Examples of fatty acids are caprylic acid, oleic acid and stearic acid Examples of sterols are cholesterol, cholesteryl esters of polar acids, phytosterols, bile acids. Also disclosed is a solution comprising one or more taxane derivatives, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or salts thereof in a water miscible solvent, which on dilution with an aqueous liquid vehicle gives a nanodispersion.
Healthy volunteers will test each of the 3 galenic forms of Lactobacillus salivarius on 3 periods of 7 days. Each period will be separated from another with a 14-day wash-out period at least.
INTRODUCTION: As of 2020, breast cancer has emerged as the predominant cause of cancer incidence globally. Anthracycline-based chemotherapy serves as a crucial element in the treatment regimen for breast cancer. However, these anthracycline-based drugs are associated with cardiac toxicity. This study represents the first clinical quantitative analysis aimed at accurately determining the incidences of arrhythmia and abnormal electrocardiogram (ECG) changes, thereby providing valuable data to bolster clinical drug usage and monitoring.
METHODS: A systematic search was conducted across multiple databases including CNKI, VIP, Wanfang, PubMed, Embase, Web of Science, and the Cochrane Library. The incidence of combined arrhythmias in breast cancer patients and the associated heterogeneity were calculated using either a random effect model or a fixed effect model. Statistical analysis was performed using STATA16.
RESULTS: The study encompassed a total of 37 articles, which included 5705 breast cancer patients undergoing anthracycline treatment. Among these patients, 2257 developed arrhythmias. The meta-analysis revealed that the incidence of anthracycline-associated arrhythmias and abnormal ECG changes in breast cancer patients was 0.41 (0.37, 0.44). Subgroup analysis indicated that the incidence of ST-T segment change was 0.19 (0.15, 0.23), the incidence of conduction block was 0.04 (0.02, 0.05), the incidence of premature beats was 0.09 (0.07, 0.11), and the incidence of atrial fibrillation was 0.04 (0.00, 0.12). Additional results are presented in Table 3.
CONCLUSION: This pioneering study accurately assesses the incidence of arrhythmias in breast cancer patients treated with anthracyclines. The findings provide clinicians with valuable insights into understanding and managing the cardiac toxicity associated with such treatment. Moreover, this study lays the foundation for future research exploring the mechanisms underlying these arrhythmias and potential preventative strategies.
Paramedics face various unconventional and secondary task demands while driving ambulances, leading to significant cognitive load, especially during lights-and-sirens responses. Previous research suggests that high cognitive load negatively affects driving performance, increasing the risk of accidents, particularly for inexperienced drivers. The current study investigated the impact of anticipatory treatment planning on cognitive load during emergency driving, as assessed through the use of a driving simulator. We recruited 28 non-paramedic participants to complete a simulated baseline drive with no task and a cognitive load manipulation using the 1-back task. We also recruited 18 paramedicine students who completed a drive while considering two cases they were travelling to: cardiac arrest and infant seizure, representing varying difficulty in required treatment. The results indicated that both cases imposed considerable cognitive load, as indicated by NASA Task Load Index responses, comparable to the 1-back task and significantly higher than driving with no load. These findings suggest that contemplating cases and treatment plans may impact the safety of novice paramedics driving ambulances for emergency response. Further research should explore the influence of experience and the presence of a second individual in the vehicle to generalise to broader emergency response driving contexts.
This population mostly includes STEACS patients not receiving reperfusion for late presentation (i.e. \> 12 hours) or patient preference. Note that patient in this category may receive diagnostic angiography for better diagnostic assessment and/or risk stratification but NOT on an urgent basis.
Parent coaches will complete interventionist training and supervision in the "Family Check-Up," an evidence-based behavioral parent training (BPT) program, including in the adaptations for families with DHH children. Each parent coach will deliver the intervention to 5 parent-child dyads.
PURPOSE:To obtain a humectant cream, capable of stabilizing urea and simultaneously suppressing a rise in pH value and having improved humectant effects, etc., after preservation for a long period, by adding an inorganic ammonium salt to a cream, prepared by using the urea and pyrrolidonecarboxylic acids together and having enhanced humectant effects. CONSTITUTION:A humectant cream obtained by normally adding (C) 0.2-3wt.% inorganic ammonium salt, such as ammonium chloride, ammonium nitrate, ammonium sulfate or ammonium phosphate, as a stabilizer for urea to a cream containing (A) about 3-25wt.% urea, (B) pyrrolidonecarboxylic acid or salt thereof, e.g. sodium or potassium salt, in an amount of about 1-5wt.% expressed in terms of 1-50% aqueous solution. Since the urea is stabilized, expected effects are attained even after preservation for a long period. Since a rise in pH value is suppressed, unpleasant ammoniacal smell is not sensed. Furthermore, the amount of evaporated water is small by blending the ingredient (C) and the aimed humectant cream having excellent humectant effects is obtained.
PROBLEM TO BE SOLVED: To obtain the subject composition useful as an antihypertensive agent by including diuretic thiazide. SOLUTION: This composition comprises either one of diuretic thiazide (e.g. chlorothiazide or flumethiazide) in an amount of 7-25wt.% based on dose required for obtaining prescribed diuresis effect, an insoluble basic hydroxymetal thiazide composed of diuretic thiazide and a metal hydroxyl compound of aluminum, etc., a salt of diuretic thiazide and EDTA calcium disoldium salt (or EDTA disodium salt), a molecular complex composed of diuretic thiazide and a long chain polymer (e.g. a hydroxyalkyl cellulose polymer) and a salt of diuretic thiazide and β-adrenalin-suppresisng amine (e.g. alprenolol) or a salt of diuretic thiazide and amiloride. The composition reduces influence by excretion amount of urine and exhibits antihypertensive action.
PCT No. PCT/EP94/01696 Sec. 371 Date Feb. 12, 1996 Sec. 102(e) Date Feb. 12, 1996 PCT Filed May 25, 1994 PCT Pub. No. WO94/27611 PCT Pub. Date Dec. 8, 1994An injection solution for subcutaneous or intramuscular administration to an animal, and a method of producing same, are provided. The injection solution is substantially free of chloride ions and employs a basic amino acid as a pH-adjusting agent, characteristics that make the injection solution more physiologically tolerable upon injection. Preferably, the injection solution comprises 5 to 30 g of oxytetracycline per 100 ml of injection solution, where the oxytetracycline is provided in a magnesium complex; 0 to 25 g of polyvinylpyrrolidone per 100 ml of injection solution; a basic amino acid in an amount sufficient to adjust a pH of the injection solution to from 5.5 to 9.5; and an additive in an aqueous/organic solvent phase.
This study is a prospective, Phase II clinical study. 20 Histologically confirmed NSCLCs with unresectable or locally advanced, recurrent or metastatic disease not suitable for radical concurrent chemo-radiotherapy, treatment naive, and confirmed PD-L1 positive with FGFR 1-3 mutations are enrolled. The participants will receive Sintilimab combined with Pemigatinib every 3 weeks (Q3W): Sintilimab is administered every 3 weeks (200mg, IV), Pemigatinib 13.5 mg once daily (QD) orally, continuous administration. The subject will continue treatment until disease progression, intolerable toxicity, withdrawal of informed consent, start of other anti-tumor treatments, death or other conditions that should be stopped as prescribed by the protocol. The longest administration time of Sintilimab is 2 years (35 cycles). In consideration of the safety of the combination therapy, this study will conduct safety monitoring on the 6 subjects initially enrolled in the safety observation period (defined as 21 days after the subjects received the study drug treatment for the first time) . After the study enrollment reaches 6 subjects, enrollment will be suspended until the safety observation period of the 6th patient is over and the conditions for continuing the study are met. If ≥2 dose-limiting toxicity (DLT) are observed in these 6 patients, the investigators will review the data and discuss, and decide to revise the dosing regimen of the follow-up study to reduce the incidence of adverse events, or terminate it completely. If DLT is less than or equal to 1 of the 6 participants, the study will continue to follow the original protocol. The primary endpoint is objective response rate, the secondary endpoints are progression free survival, duration of response, time to response, disease control rate, overall survival, safety and tolerance.
Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 2 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
The present invention is a foamable alcohol having at least one active ingredient. The active ingredient can be a prescription or non-prescription drug or medication. It either works on the skin or is absorbed transdermally and works on the body. Alcohol, such as ethyl alcohol is combined with a fluoro-surfactant, at least one active ingredient and water. Optionally, inactive ingredients can be added. The fluoro-surfactant reduces the surface tension of the alcohol allowing it to be foamed without reducing the effectiveness of the alcohol as a carrier for the active ingredient or the efficacy of the active ingredient(s). The inventive mixture foams when dispensed as an aerosol or pumped through a foam pump. The pump or other dispenser doses the alcohol. The foam is easy to apply, and liquefies as a user smears it on a surface.
1,167,196. Lactic acid bacteria. YAKULT HONSHA K.K. Dec.12, 1966, No.55496/66. Heading C6F. Lactic acid bacteria of the species Lactobacillus acidophilus resistant to acidities of the order of pH 3À2, are propagated by the following steps: (i) keeping either the excrement of infants (less than 6 months old) fed on mother's milk or vaginal secretions in an acidic solution of pH 3À1-3À3 and at a temperature of 35‹ -40‹C. for 3-24 hours, (ii) isolating and cultivating the surviving bacteria (only Lactobacillus acidophilus survives the acidity), (iii) passing the bacteria through mammalian (human) intestines one or more times and (iv) separating the conditioned lactic acid bacteria from the excrement by a further treatment in acid.
Obesity has been increasing worldwide and is well-known as a risk factor for cognitive decline. It has been reported that oxidative stress in the brain is deeply involved in cognitive dysfunction in rodent models. While there are many studies on oxidation in the liver and adipose tissue of obese mice, the relationship between obesity-induced cognitive dysfunction and brain oxidation has not been elucidated. Here, we show that obesity induced by a high-fat, high-sucrose diet (HFSD) alters cognitive function in C57BL/6 male mice, and it may involve the acceleration of brain oxidation. Tocotrienols (T3s), which are members of the vitamin E family, can prevent HFSD-induced cognitive changes. To elucidate these mechanisms, respiratory metabolism, locomotor activity, temperature around brown adipose tissue, and protein profiles in the cerebrum cortex were measured. Contrary to our expectation, respiratory metabolism was decreased, and temperature around brown adipose tissue was increased in the feeding of HFSD. The proteins that regulate redox balance did not significantly change, but 12 proteins, which were changed by HFSD feeding and not changed by T3s-treated HFSD compared to control mice, were identified. Our results indicated that HFSD-induced obesity decreases mouse learning ability and that T3s prevent its change. Additionally, feeding of HFSD significantly increased brain oxidation. However, further study is needed to elucidate the mechanisms of change in oxidative stress in the brain by obesity.
The Wee Sight® Transilluminator (Philips Children's Medical Ventures, Monroeville, PA) is a hand held, non-heat producing, light emitting diode (Class 2), battery operated device. The device assists in vein identification by being held adjacent to or under the subject's extremity to visualize the venous anatomy superficial veins absorb light and appear as dark lines against the surrounding illuminated tissues. This will be used to identify veins during peripheral intravenous line (PIV) insertion procedures.
A computing device accepts an examination task to be carried out by a medical imaging device from an operator. An implementation of the examination task to be realized is accepted and assigned to the examination task. Based upon the data typifying the person to be examined and data defining the type of examination of the examination task, it then establishes possible implementations of the examination task. The database contains data typifying the person, broken down according to the person to be examined, type of examination, medical imaging device and settings of the medical imaging device, a medical technology assessment of the respective examination and a commercial assessment of the respective examination. It specifies the established possible implementations together with the two for selection. Based upon the implementation to be realized, a flowchart is updated so that the flowchart contains what is now the examination task and the assigned implementation.
PURPOSE: We present a technique for covering large midline loss of abdominal wall using a novel method by autologous tissues.
METHODS: Twenty-two patients (body mass index = 35,6 ± 6,9 kg/m2) were involved in the prospective cohort study. Acute and elective cases were included. The gap area was 450.1 ± 54 cm2. The average width of the midline gap was 16,3 ± 3,2 cm. The rectus muscles were mobilized from its posterior sheath. Both muscles were turned by180º medially, so that the complete abdominal wall gap could be covered without considerable tension. Changes in intra-abdominal pressure, quality of life and hernia recurrency were determined.
RESULTS: There was no significant increase in the intra-abdominal pressure. Wound infection and seroma occurred in four cases. Bleeding occurred in one case. Pre- and post-operative quality of life index significantly improved (23 ± 13 vs. 47 ± 6; p = 0,0013). One recurrent hernia was registered. The procedure could be performed safely and yielded excellent results. The method was applied in acute cases. The intact anatomical structure of rectus muscles was essential.
CONCLUSIONS: The midline reconstruction with bilateral turned-over rectus muscles provided low tension abdominal wall status, and it did not require synthetic mesh implantation.